AstraZeneca

AstraZeneca, Sanofi, Eli Lilly sue HHS over 340B opinion
AstraZeneca, Sanofi, Eli Lilly sue HHS over 340B opinion
Beckers Hospital Review
Eli Lilly
Sanofi
AstraZeneca
HHS
340B
discounts
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
Pharmaforum
AstraZeneca
Daiichi Sankyo
stomach cancer
Enhertu
Roche
Herceptin
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
10 key clinical trials to watch in the first half of 2021
10 key clinical trials to watch in the first half of 2021
BioPharma Dive
clinical trials
Novavax
AstraZeneca
JNJ
vaccines
COVID-19
Biomarin
Amgen
Merck
Pfizer
Roche
SAGE Therapeutics
Biogen
Vertex Pharmaceuticals
Flag link:
AstraZeneca's Farxiga gets rough FDA review date for groundbreaking move into chronic kidney disease
AstraZeneca's Farxiga gets rough FDA review date for groundbreaking move into chronic kidney disease
Endpoints
AstraZeneca
Farxiga
FDA
chronic kidney disease
Flag link:
Newly acquired Alexion pays $100M for Rhythm's speedy review voucher
Newly acquired Alexion pays $100M for Rhythm's speedy review voucher
Fierce Biotech
AstraZeneca
Alexion
Rhythm
priority review vouchers
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
US won't get AstraZeneca COVID-19 vaccine until April, Warp Speed chief says
US won't get AstraZeneca COVID-19 vaccine until April, Warp Speed chief says
Beckers Hospital Review
COVID-19
vaccines
AstraZeneca
Moncef Slaoui
Flag link:
First person receives AstraZeneca’s COVID-19 vaccine in the UK
First person receives AstraZeneca’s COVID-19 vaccine in the UK
Biopharma Reporter
AstraZeneca
vaccines
UK
COVID-19
Flag link:
Corporate and regulatory developments over the holidays
Corporate and regulatory developments over the holidays
EP Vantage
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
Flag link:
10 Biopharma Stories to Look Forward to in 2021
10 Biopharma Stories to Look Forward to in 2021
BioSpace
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca
Flag link:
Pfizer Criticizes Sudden Change in Coronavirus Vaccine Dosing Regime in the U.K.
Pfizer Criticizes Sudden Change in Coronavirus Vaccine Dosing Regime in the U.K.
Motley Fool
Pfizer
BioNTech
vaccines
UK
BNT162b2
AstraZeneca
AZD1222
COVID-19
Flag link:
AstraZeneca's COVID-19 vaccine gets the green light in the UK
AstraZeneca's COVID-19 vaccine gets the green light in the UK
Biopharma Reporter
UK
COVID-19
vaccines
AstraZeneca
Flag link:
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Flag link:
UK expected to approve Oxford-AstraZeneca Covid vaccine this week
UK expected to approve Oxford-AstraZeneca Covid vaccine this week
CNBC
UK
vaccines
COVID-19
AstraZeneca
Flag link:
Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan
Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan
Motley Fool
Merck
AstraZeneca
Japan
ovarian cancer
prostate cancer
pancreatic cancer
Lynparza
Flag link:
Amgen-AstraZeneca Experimental Asthma Drug Surprisingly Flops in Phase III
Amgen-AstraZeneca Experimental Asthma Drug Surprisingly Flops in Phase III
BioSpace
Amgen
AstraZeneca
asthma
clinical trials
tezepelumab
Flag link:
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
AstraZeneca, FibroGen's roxadustat hits snag at FDA, but analysts figure an approval's still on its way
Fierce Pharma
AstraZeneca
FibroGen
roxadustat
FDA
anemia
Flag link:
The top 5 pharma M&A deals of 2020
The top 5 pharma M&A deals of 2020
Pharmaforum
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Flag link:

Pages